These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8726544)

  • 41. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.
    Fox S; Silverdale M; Kellett M; Davies R; Steiger M; Fletcher N; Crossman A; Brotchie J
    Mov Disord; 2004 May; 19(5):554-60. PubMed ID: 15133820
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Acute detoxification of opioid-addicted patients with naloxone during propofol or methohexital anesthesia: a comparison of withdrawal symptoms, neuroendocrine, metabolic, and cardiovascular patterns.
    Kienbaum P; Scherbaum N; Thürauf N; Michel MC; Gastpar M; Peters J
    Crit Care Med; 2000 Apr; 28(4):969-76. PubMed ID: 10809268
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of polydipsia and hyponatremia in psychiatric patients. Can clozapine be a new option?
    de Leon J; Verghese C; Stanilla JK; Lawrence T; Simpson GM
    Neuropsychopharmacology; 1995 Apr; 12(2):133-8. PubMed ID: 7779241
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New and experimental therapeutic roles for naloxone and related opioid antagonists.
    McNicholas LF; Martin WR
    Drugs; 1984 Jan; 27(1):81-93. PubMed ID: 6319107
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacological challenge with naloxone and cue exposure in alcohol dependence: results of a randomized, double-blind placebo-controlled trial.
    Lieb M; Palm U; Chiang S; Laubender RP; Nothdurfter C; Sarubin N; Mokhtari-Nejad R; Koller G; Soyka M
    World J Biol Psychiatry; 2013 Sep; 14(7):539-46. PubMed ID: 24020866
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.
    Ling W; Hillhouse MP; Saxon AJ; Mooney LJ; Thomas CM; Ang A; Matthews AG; Hasson A; Annon J; Sparenborg S; Liu DS; McCormack J; Church S; Swafford W; Drexler K; Schuman C; Ross S; Wiest K; Korthuis PT; Lawson W; Brigham GS; Knox PC; Dawes M; Rotrosen J
    Addiction; 2016 Aug; 111(8):1416-27. PubMed ID: 26948856
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clozapine treatment of a schizophrenic patient with polydipsia and hyponatremia.
    Wakefield T; Colls I
    Am J Psychiatry; 1996 Mar; 153(3):445-6. PubMed ID: 8610846
    [No Abstract]   [Full Text] [Related]  

  • 48. Effects of naloxone, beta-endorphin and ACTH on acquisition of schedule-induced polydipsia.
    Tazi A; Dantzer R; Mormede P; Le Moal M
    Psychopharmacology (Berl); 1985; 85(1):87-91. PubMed ID: 2984711
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Addition of ultralow dose naloxone to postoperative morphine PCA: unchanged analgesia and opioid requirement but decreased incidence of opioid side effects.
    Cepeda MS; Alvarez H; Morales O; Carr DB
    Pain; 2004 Jan; 107(1-2):41-6. PubMed ID: 14715387
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intravenous naloxone administration in schizophrenia and affective illness.
    Davis GC; Bunney WE; DeFraites EG; Kleinman JE; van Kammen DP; Post RM; Wyatt RJ
    Science; 1977 Jul; 197(4298):74-7. PubMed ID: 325650
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Endogenous opioid peptides and regulation of drinking and feeding.
    Reid LD
    Am J Clin Nutr; 1985 Nov; 42(5 Suppl):1099-132. PubMed ID: 2865892
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Death from self-induced water intoxication among patients with schizophrenic disorders.
    Vieweg WV; David JJ; Rowe WT; Wampler GJ; Burns WJ; Spradlin WW
    J Nerv Ment Dis; 1985 Mar; 173(3):161-5. PubMed ID: 3973577
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multidisciplinary approach to psychosis, intermittent hyponatremia, and polydipsia.
    Leadbetter RA; Shutty MS; Higgins PB; Pavalonis D
    Schizophr Bull; 1994; 20(2):375-85. PubMed ID: 8085139
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Naloxone treatment for irritable bowel syndrome--a randomized controlled trial with an oral formulation.
    Hawkes ND; Rhodes J; Evans BK; Rhodes P; Hawthorne AB; Thomas GA
    Aliment Pharmacol Ther; 2002 Sep; 16(9):1649-54. PubMed ID: 12197844
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Naloxone-induced reduction of schizophrenic symptoms.
    Jørgensen HA; Cappelen C
    Acta Psychiatr Scand; 1982 May; 65(5):370-4. PubMed ID: 6126068
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recurrent rhabdomyolysis in a teenager with psychosis-intermittent hyponatremia-polydipsia syndrome.
    Shenoi AN; Stockwell J
    Pediatr Emerg Care; 2015 Apr; 31(4):274-6. PubMed ID: 25831029
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of naloxone and naltrexone on the increased water intake and drinking duration in phenobarbitone-treated rats.
    Cooper SJ; McGivern H
    Psychopharmacology (Berl); 1983; 79(1):25-8. PubMed ID: 6403960
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Polydipsia and hyponatremia.
    Liberman RP; Marshall BD
    Hosp Community Psychiatry; 1993 Feb; 44(2):184; author reply 185-6. PubMed ID: 8432507
    [No Abstract]   [Full Text] [Related]  

  • 59. Oral sodium chloride in the management of schizophrenic patients with self-induced water intoxication.
    Vieweg WV; Rowe WT; David JJ; Spradlin WW
    J Clin Psychiatry; 1985 Jan; 46(1):16-9. PubMed ID: 3965438
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mindfulness Meditation Modulates Pain Through Endogenous Opioids.
    Sharon H; Maron-Katz A; Ben Simon E; Flusser Y; Hendler T; Tarrasch R; Brill S
    Am J Med; 2016 Jul; 129(7):755-8. PubMed ID: 27039954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.